Alexion Pharmaceuticals, Inc. (ALXN) Shares Sold by Mitsubishi UFJ Asset Management UK Ltd.

Mitsubishi UFJ Asset Management UK Ltd. cut its stake in shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 27.3% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 8,000 shares of the biopharmaceutical company’s stock after selling 3,000 shares during the quarter. Mitsubishi UFJ Asset Management UK Ltd.’s holdings in Alexion Pharmaceuticals were worth $1,112,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Nisa Investment Advisors LLC grew its holdings in shares of Alexion Pharmaceuticals by 30.7% during the third quarter. Nisa Investment Advisors LLC now owns 53,681 shares of the biopharmaceutical company’s stock valued at $7,462,000 after buying an additional 12,616 shares during the last quarter. Andra AP fonden lifted its position in Alexion Pharmaceuticals by 41.7% during the third quarter. Andra AP fonden now owns 17,000 shares of the biopharmaceutical company’s stock valued at $2,363,000 after purchasing an additional 5,000 shares during the period. First Hawaiian Bank acquired a new position in Alexion Pharmaceuticals during the third quarter valued at $102,000. Hills Bank & Trust Co. lifted its position in Alexion Pharmaceuticals by 6.3% during the third quarter. Hills Bank & Trust Co. now owns 7,744 shares of the biopharmaceutical company’s stock valued at $1,076,000 after purchasing an additional 456 shares during the period. Finally, Gradient Investments LLC lifted its position in Alexion Pharmaceuticals by 37.3% during the third quarter. Gradient Investments LLC now owns 8,256 shares of the biopharmaceutical company’s stock valued at $1,148,000 after purchasing an additional 2,242 shares during the period. 93.06% of the stock is currently owned by hedge funds and other institutional investors.

A number of research analysts recently issued reports on the stock. BidaskClub upgraded shares of Alexion Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Saturday, September 29th. Barclays boosted their target price on shares of Alexion Pharmaceuticals to $175.00 and gave the company an “overweight” rating in a research report on Friday, September 28th. Evercore ISI restated an “outperform” rating and set a $158.00 target price on shares of Alexion Pharmaceuticals in a research report on Thursday, July 26th. JPMorgan Chase & Co. boosted their target price on shares of Alexion Pharmaceuticals from $184.00 to $188.00 and gave the company an “overweight” rating in a research report on Friday, July 27th. Finally, Jefferies Financial Group restated a “hold” rating and set a $123.00 target price on shares of Alexion Pharmaceuticals in a research report on Friday, July 27th. One analyst has rated the stock with a sell rating, four have assigned a hold rating and sixteen have issued a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $160.74.

Shares of Alexion Pharmaceuticals stock traded down $0.03 during trading hours on Wednesday, reaching $127.67. The stock had a trading volume of 9,225 shares, compared to its average volume of 1,761,061. The company has a market cap of $30.98 billion, a P/E ratio of 24.66, a price-to-earnings-growth ratio of 1.27 and a beta of 0.79. Alexion Pharmaceuticals, Inc. has a twelve month low of $102.10 and a twelve month high of $144.91. The company has a debt-to-equity ratio of 0.33, a quick ratio of 2.27 and a current ratio of 2.72.

Alexion Pharmaceuticals (NASDAQ:ALXN) last issued its quarterly earnings data on Thursday, July 26th. The biopharmaceutical company reported $2.07 earnings per share for the quarter, topping analysts’ consensus estimates of $1.49 by $0.58. The business had revenue of $1.05 billion during the quarter, compared to the consensus estimate of $976.81 million. Alexion Pharmaceuticals had a negative net margin of 2.68% and a positive return on equity of 15.21%. The company’s revenue was up 14.5% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.56 earnings per share. Equities research analysts forecast that Alexion Pharmaceuticals, Inc. will post 6.45 EPS for the current year.

About Alexion Pharmaceuticals

Alexion Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers Soliris (eculizumab), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; atypical hemolytic uremic syndrome (aHUS), a genetic disease; and generalized myasthenia gravis, a debilitating, complement-mediated neuromuscular disease.

Featured Story: Google Finance Portfolio Workaround

Institutional Ownership by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply